Managing Dry Skin Using Lipid Replacement Therapy
Trial data of a novel moisturizer containing skin lipids and humectants vs a reference emollient cream without these additives for dry skin treatment is reviewed.
Dermatitis
The Most Common Causes of Pediatric Allergic Contact Dermatitis
The clinical profile of pediatric patients with allergic contact dermatitis (ACD) is identified.
FDA Approves Rinvoq for Treatment of Atopic Dermatitis
Approval indicated for those 12 years and older with atopic dermatitis that has not responded to previous treatment
Cibinqo Approved for Refractory, Moderate to Severe Atopic Dermatitis
The approval was based on data from the phase 3 JADE clinical trial program, which included the JADE MONO-1, JADE MONO-2, and JADE COMPARE trials.
Rinvoq Gains FDA Approval for Atopic Dermatitis
The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.
Rapid, Sustained Disease Control with Dupilumab for Atopic Dermatitis
Self-reported disease control and quality of life in patients with atopic dermatitis treated with dupilumab is assessed.
Topical Corticosteroids Effective for Staphylococcus aureus in Hand Eczema
The density of S. aureus colonization in patients with hand eczema (HE) after topical corticosteroids (TCS) treatment is investigated.
Atopic Dermatitis Associated With Poor School Behavior in Childhood, Adolescence
Data from the Fragile Families and Child Wellbeing Study was reviewed for relationships between atopic dermatitis (AD) and poor school behaviors in younger students.
Colophony is Most Common Medical Adhesive Allergen in ACD
The demographics, clinical characteristics, patch test results, and occupational data for patients with medical adhesive contact allergy are characterized.
Adbry Approved for Moderate to Severe Atopic Dermatitis
The approval was based on data from 3 pivotal phase 3 (ECZTRA 1-3) trials that evaluated the safety and efficacy of Adbry in 1934 adults with moderate to severe AD.
- Loading...
Loading...
Next post in Dermatitis
Loading... 
Loading...